EUVIMEDEUVIMED entdecken
CrossrefInfokarte

FCM marker importance for MRD assessment in T‐cell acute lymphoblastic leukemia: An AIEOP‐BFM‐ALL‐FLOW study group report

Florian Kowarsch, Margarita Maurer‐Granofszky, Lisa Weijler, Matthias Wödlinger, Michael Reiter, Angela Schumich, Tamar Feuerstein, Simona Sala, Michaela Nováková, Giovanni Faggin, Giuseppe Gaipa, Ondrej Hrusak, Barbara Buldini, Michael N. Dworzak

Cytometry Part A · 2024-01 · 105 (1) · 24-35

DOI: 10.1002/cyto.a.24805 ↗
AbstractBibliografische Angaben

Abstract

Abstract T‐lineage acute lymphoblastic leukemia (T‐ALL) accounts for about 15% of pediatric and about 25% of adult ALL cases. Minimal/measurable residual disease (MRD) assessed by flow cytometry (FCM) is an important prognostic indicator for risk stratification. In order to assess the MRD a limited number of antibodies directed against the most discriminative antigens must be selected. We propose a pipeline for evaluating the influence of different markers for cell population classification in FCM data. We use linear support vector machine, fitted to each sample individually to avoid issues with patient and laboratory variations. The best separating hyperplane direction as well as the influence of omitting specific markers is considered. Ninety‐one bone marrow samples of 43 pediatric T‐ALL patients from five reference laboratories were analyzed by FCM regarding marker importance for blast cell identification using combinations of eight different markers. For all laboratories, CD48 and CD99 were among the top three markers with strongest contribution to the optimal hyperplane, measured by median separating hyperplane coefficient size for all samples per center and time point (diagnosis, Day 15, Day 33). Based on the available limited set tested (CD3, CD4, CD5, CD7, CD8, CD45, CD48, CD99), our findings prove that CD48 and CD99 are useful markers for MRD monitoring in T‐ALL. The proposed pipeline can be applied for evaluation of other marker combinations in the future.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →